Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice.
diagnosis
myeloproliferative neoplasms
polycythaemia vera
primary myelofibrosis
prognosis
treatment
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
25
05
2023
accepted:
31
05
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Primary myelofibrosis (PMF) and polycythaemia vera (PV) are rare
Identifiants
pubmed: 37601853
doi: 10.1002/jha2.734
pii: JHA2734
pmc: PMC10435696
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
779-791Informations de copyright
© 2023 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
Shanti Amé participated in advisory boards for Bristol Myers Squibb and Novartis. Fiorenza Barraco declares no competing financial interests. Jean‐Christophe Ianotto received speaker fees from Novartis. Eric Jourdan participated in advisory boards for Bristol Myers Squibb, Novartis and AbbVie. Jérôme Rey participated in advisory boards for Bristol Myers Squibb, Novartis and AbbVie. Jean‐François Viallard received speaker fees from AOP Orphan, Novartis, Bristol Myers Squibb, AbbVie and Gilead. Mathieu Wémeau participated in advisory boards for AbbVie, AOP Orphan, Bristol Myers Squibb and Novartis, and received speaker fees from Novartis. Jean‐Jacques Kiladjian received consulting fees from AbbVie and Novartis, speaker fees from AOP Orphan, Novartis and Bristol Myers Squibb, and participated in advisory boards for Incyte.
Références
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood Cancer J. 2016 Aug 19;6(8):e459
pubmed: 27540717
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Lancet Haematol. 2020 Mar;7(3):e196-e208
pubmed: 32014125
N Engl J Med. 2017 Jun 1;376(22):2168-2181
pubmed: 28564565
Am J Hematol. 2013 Aug;88(8):665-9
pubmed: 23657863
Biol Blood Marrow Transplant. 2019 Mar;25(3):522-528
pubmed: 30408564
Am J Hematol. 2021 Jan;96(1):69-79
pubmed: 33064301
Br J Haematol. 2011 Feb;152(3):331-9
pubmed: 21133885
J Clin Oncol. 2016 Jan 10;34(2):151-9
pubmed: 26598745
Blood Cancer J. 2021 Mar 6;11(3):53
pubmed: 33677466
Ann Hematol. 2020 Nov;99(11):2555-2564
pubmed: 32382773
Rev Bras Hematol Hemoter. 2015 Sep-Oct;37(5):348-53
pubmed: 26408371
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Mayo Clin Proc. 2012 Jan;87(1):25-33
pubmed: 22212965
Can Oncol Nurs J. 2018 Oct 1;28(4):262-268
pubmed: 31148835
Biol Blood Marrow Transplant. 2010 Mar;16(3):358-67
pubmed: 19879949
Hematol Oncol Clin North Am. 2021 Apr;35(2):391-407
pubmed: 33641876
Blood Cancer J. 2017 Dec 15;7(12):648
pubmed: 29242616
Leukemia. 2013 Sep;27(9):1861-9
pubmed: 23619563
Blood. 2012 Feb 9;119(6):1363-9
pubmed: 22160617
Lancet Haematol. 2022 Apr;9(4):e301-e311
pubmed: 35358444
EJHaem. 2023 Jun 07;4(3):779-791
pubmed: 37601853
Leukemia. 2022 Jul;36(7):1703-1719
pubmed: 35732831
Am J Hematol. 2016 Dec;91(12):1262-1271
pubmed: 27870387
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Leukemia. 2021 Dec;35(12):3551-3560
pubmed: 34023851
Blood. 2009 Mar 26;113(13):2895-901
pubmed: 18988864
Korean J Intern Med. 2020 Jan;35(1):1-11
pubmed: 31778606
Haematologica. 2020 Mar;105(3):e95-e97
pubmed: 31413086
Mayo Clin Proc. 2019 Apr;94(4):599-610
pubmed: 30824279
Ann Hematol. 2020 Jul;99(7):1441-1451
pubmed: 32417942
Leukemia. 2018 Sep;32(9):2077-2081
pubmed: 29955128
Bone Marrow Transplant. 2020 Apr;55(4):708-716
pubmed: 31534197
Curr Hematol Malig Rep. 2018 Jun;13(3):164-172
pubmed: 29796726
Hemasphere. 2017 Dec 20;1(1):e1
pubmed: 31723730
Korean J Intern Med. 2018 Jul;33(4):679-690
pubmed: 29665657
Am J Hematol. 2021 Jan;96(1):80-88
pubmed: 33108024
J Clin Oncol. 2021 Sep 10;39(26):2881-2892
pubmed: 34138638
Rev Bras Hematol Hemoter. 2016 Jul-Sep;38(3):257-63
pubmed: 27521865
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Am J Clin Pathol. 2017 May 01;147(5):444-452
pubmed: 28419183
Ther Clin Risk Manag. 2021 Mar 16;17:209-221
pubmed: 33758507
Blood. 2010 Mar 4;115(9):1703-8
pubmed: 20008785
Cancer. 2006 Jul 15;107(2):361-70
pubmed: 16770787
Ther Adv Hematol. 2020 Feb 13;11:2040620720906002
pubmed: 32110286
Bone Marrow Transplant. 2021 Aug;56(8):1888-1899
pubmed: 33767402
Leukemia. 2021 Jan;35(1):1-17
pubmed: 32647323
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
J Hematol Oncol. 2017 Sep 29;10(1):156
pubmed: 28962635
J Cancer Res Clin Oncol. 2016 Sep;142(9):2041-9
pubmed: 27431664
Blood Adv. 2022 Jan 25;6(2):373-375
pubmed: 34753179
Eur J Haematol. 2014 Apr;92(4):289-97
pubmed: 24372927
Lancet Haematol. 2021 Mar;8(3):e175-e184
pubmed: 33476571
Oncology. 2017;92(4):179-189
pubmed: 28095380
J Clin Oncol. 2022 May 20;40(15):1671-1680
pubmed: 35180010
Blood Adv. 2021 Mar 9;5(5):1442-1451
pubmed: 33666653
Blood. 2000 Apr 1;95(7):2226-33
pubmed: 10733489
J Clin Oncol. 2011 Oct 10;29(29):3907-13
pubmed: 21911721
Curr Hematol Malig Rep. 2021 Oct;16(5):473-482
pubmed: 34478054
Hemasphere. 2020 Jul 21;4(4):e424
pubmed: 32903304
Cells. 2022 Feb 05;11(3):
pubmed: 35159362
Leukemia. 2022 May;36(5):1408-1411
pubmed: 35210530
Future Oncol. 2015;11(5):719-33
pubmed: 25757677
Leukemia. 2015 Nov;29(11):2126-33
pubmed: 26293647
Leukemia. 2021 Dec;35(12):3339-3351
pubmed: 34480106
J Clin Oncol. 2018 Feb 1;36(4):310-318
pubmed: 29226763
Am J Hematol. 2021 Jan;96(1):145-162
pubmed: 33197049
Biol Blood Marrow Transplant. 2016 Mar;22(3):432-40
pubmed: 26493563
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):480-488
pubmed: 29222296
Haematologica. 2016 Jun;101(6):660-71
pubmed: 27252511
Br J Haematol. 2019 Jan;184(2):176-191
pubmed: 30478826
Am Health Drug Benefits. 2014 Oct;7(7 Suppl 3):S36-47
pubmed: 26568781
Blood. 2008 May 15;111(10):4922-9
pubmed: 18250227
Cancer Treat Rev. 2017 Feb;53:47-52
pubmed: 28063304
Am J Hematol. 2020 Dec;95(12):1599-1613
pubmed: 32974939
Blood. 2022 Sep 15;140(11):1200-1228
pubmed: 35767897